1 / 8

Purpose

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved. Purpose

paki-beasley
Download Presentation

Purpose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved Purpose To determine whether the angiotensin II receptor blocker candesartan is beneficial in patients with chronic heart failure (CHF) and preserved left ventricular systolicfunction Reference Yusuf S, Pfeffer MA, Swedberg K, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777–81.

  2. CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved- TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, placebo-controlled Patients 3023 patients aged >18 years with symptomatic CHF (NYHA class II–IV), who had left ventricular ejection fraction >40% Follow up and primary endpoint Primary endpoint: cardiovascular death or hospital admission for CHF. Median 36.6 months follow up. Treatment Placebo or candesartan titrated to 32 mg oncedaily

  3. Placebo Candesartan Placebo Candesartan (n=1509) (n=1514) (n=1509) (n=1514) 67.1 67.2 44 45 59 61 28 29 64 65 60 62 39 37 57 56 1 2 9 9 23 22 36 35 34 36 19 20 31 29 56 56 12 11 136.3 136.0 59 58 77.8 77.8 43 41 CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved- TRIAL DESIGN continued- Baseline characteristics (%) Age (years)a History MI Male Diabetes mellitus NYHA class: Hypertension II Heart failure cause III Ischemic IV Idiopathic Hypertensive LVEF 41–49% Medications 50–59% ACE inhibitor >60% Beta-blocker BP (mmHg)a Spironolactone Systolic Aspirin Diastolic Lipid-lowering drug aMean Yusuf et al. Lancet 2003;362:777–81.

  4. CHARM-Preserved:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved- RESULTS - • Nonsignificant trend to reduction in primary outcome of cardiovascular death or hospital admission for CHF in candesartan group compared with placebo (22 vs. 24.3%, P=0.118) • Secondary outcomes – composites of primary outcome and MI, nonfatal stroke and coronary revascularization – also showed nonsignificant trend • Total number of hospital admissions for CHF significantly reduced in candesartan group (402 vs. 566, P=0.014) • All-cause mortality similar in both groups (244 vs. 237 patients) • Permanent discontinuation due to adverse event or laboratory abnormality more frequent with candesartan (17.8 vs. 13.5%, P=0.001)

  5. Hazard ratio 0.89 (95% CI 0.77–1.03) P = 0.118 Placebo Candesartan CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved- RESULTS continued - Cardiovascular death or hospital admission for CHF Proportion 50 with event (%) 40 30 20 10 0 0 1.0 2.0 3.0 3.5 Years after randomization Yusuf et al. Lancet 2003;362:777–81.

  6. Cardiovascular death 170 (11.3) 170 (11.2) 0.99 (0.80–1.22) 0.918 Hospital admission for CHF 276 (18.3) 241 (15.9) 0.85 (0.72–1.01) 0.072 Cardiovascular death, hospital 399 (26.4) 365 (24.1) 0.90 (0.78–1.03) 0.126 admission for CHF, or MI Cardiovascular death, hospital 429 (28.4) 388 (25.6) 0.88 (0.77–1.01) 0.078 admission for CHF, MI, or stroke Cardiovascular death, hospital 497 (32.9) 460 (30.4) 0.91 (0.80–1.03) 0.123 admission for CHF, MI, stroke, or coronary revascularization CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Preserved- RESULTS continued - Primary and secondary outcomes Placebo Candesartan Hazard ratio P (n=1509) (n=1514) (95% CI) No. (%) No. (%) Cardiovascular death or 366 (24.3) 333 (22.0) 0.89 (0.77–1.03) 0.118 hospital admission for CHF Yusuf et al. Lancet 2003;362:777–81.

  7. 17 (1.1) 37 (2.4) 0.009 Hypotension 36 (2.4) 72 (4.8) 0.0005 Increase in creatinine 9 (0.6) 22 (1.5) 0.029 Hyperkalemia Any adverse event or laboratory abnormality 204 (13.5) 270 (17.8) 0.001 CHARM-Preserved:Candesartan in Heart failure: Assessment ofReduction in Mortality and morbidity -Preserved- RESULTS continued - Discontinuation because of adverse events Placebo Candesartan (n=1509) (n=1514) P Cause of discontinuation No. (%) No. (%) Yusuf et al. Lancet 2003;362:777–81.

  8. CHARM-Preserved:Candesartan in Heart failure: Assessment ofReduction in Mortality and morbidity -Preserved- SUMMARY - In patients who had symptomatic CHF and preserved left ventricular systolicfunction, with candesartan there was no significant reduction of the following, although the trend was favorable: • Cardiovascular death or hospitalization for CHF • Secondary outcomes that combined these with MI, stroke and coronary revascularization procedures However, the total number of hospital admissions for CHF was significantly reduced in the candesartan group.

More Related